Thank you for joining us in 2022!

Blood Cancer Immunotherapy

November 12, 2022, 1:50 pm -
2:20 pm
Cell therapies transforming treatment

Session Description

More than 175,000 new cases of leukemia, lymphoma, and multiple myeloma are expected this year in the United States. Fortunately, a revolution in blood cancer treatment has arrived with immune checkpoint blockade and CAR T cell therapies providing new options for patients. Several immunotherapies are already FDA-approved, and ongoing research demonstrates even greater potential for new treatments, especially in adoptive cell therapy. Join Dr. Marcel van den Brink of Memorial Sloan Kettering Cancer Center in a Q&A discussion about different immunotherapies used in the treatment of blood cancers and new treatments in development to bring the benefits of immunotherapy to even more patients.


Marcel van den Brink, MD, PhD

Memorial Sloan Kettering Cancer Center

Marcel van den Brink is a physician scientist and medical oncologist who performs both laboratory and clinical research related to allogeneic bone marrow transplantation (BMT) and immuno-oncology. He is the Head of the Division of Hematologic Malignancies at Memorial Sloan Kettering Cancer Center (MSKCC) and holds a joint appointment in the Immunology and Transplantation Program of the Sloan Kettering Institute. He is the Co-Director of the Parker Institute for Cancer Immunotherapy at MSKCC and Chairman of the Board of DKMS, an international nonprofit organization devoted to bone marrow donor registration. As a clinical scientist, he is involved in immunotherapeutic trials of cytokines, cell therapies, as well as strategies to manipulate the intestinal microbiome for patients with hematologic malignancies. His laboratory is devoted to the immunology of BMT and he studies immune reconstitution, pathophysiology of graft-versus-host disease, the intestinal microbiota, and chimeric antigen receptor T cells in patients and preclinical models. Both as a Division Head and a laboratory Principal Investigator, he mentors junior faculty members, hematology oncology fellows, postdoctoral fellows, graduate students, and undergraduate students.